Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

16.05.23	Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease (GlobeNewswire)
26.04.23	FDA Grants Accelerated Approval For Biogen's ALS Drug (RTTNews)
25.04.23	FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS (GlobeNewswire)
25.04.23	Biogen Q1 Results Top Estimates; Reaffirms FY23 Outlook (RTTNews)
24.04.23	Ausblick: Biogen legt Zahlen zum jüngsten Quartal vor (finanzen.net)
31.03.23	Biotech Stocks Facing FDA Decision In April 2023 (RTTNews)
31.03.23	Eisai, Biogen Present Lecanemab New Analyses In Phase 3 Trial; Detailed Analyses In Phase IIb Trial (RTTNews)
31.03.23	ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS (PR Newswire)
31.03.23	EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING (PR Newswire)
31.03.23	Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting (GlobeNewswire)
31.03.23	Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals (GlobeNewswire)
29.03.23	Biogen: BIIB080 Phase 1b Study Shows Reduction Of Tau PET Across Brain Regions (RTTNews)
29.03.23	New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease (GlobeNewswire)
23.03.23	Biogen Updates On FDA Advisory Committee Meeting On Tofersen For SOD1-ALS (RTTNews)
23.03.23	Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS (GlobeNewswire)
16.03.23	Biogen Gets Favorable EU Court Ruling For TECFIDERA Regulatory Data And Marketing Protection (RTTNews)
16.03.23	Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection (GlobeNewswire)
08.03.23	Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors (GlobeNewswire)
06.03.23	FDA Grants Priority Review For Approval Of Eisai's Leqembi For Alzheimer's Disease Treatment (RTTNews)
06.03.23	FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease (GlobeNewswire)
06.03.23	FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease (PR Newswire)
02.03.23	Roche-Aktie dreht ins Plus: Roche-Tochter Genentech verklagt angeblich Biogen wegen fehlender Lizenzgebühren (AWP) Die Roche-Tochter Genentech hat laut einem Bericht der Nachrichtenagentur Reuters am Dienstag den Konkurrenten Biogen vor einem Bundesgericht in San Francisco verklagt.» mehr
28.02.23	Biotech Stocks Facing FDA Decision In March 2023 (RTTNews)
28.02.23	Biogen Says BLA For Lecanemab Gets Priority Review By NMPA In China (RTTNews)
28.02.23	BIOLOGICS LICENSE APPLICATION FOR LECANEMAB DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (PR Newswire)
28.02.23	Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration (GlobeNewswire)
15.02.23	MÄRKTE USA/Wall Street zwischen Zinsangst und Konjunkturhoffnung (Dow Jones)
15.02.23	Biogen Q4 Results Top Estimates (RTTNews)
15.02.23	Biogen Inc. Q4 Profit Increases, beats estimates (RTTNews)
14.02.23	Ausblick: Biogen zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
06.02.23	Sage Therapeutics: FDA To Review NDA For Zuranolone - Quick Facts (RTTNews)
31.01.23	Erste Schätzungen: Biogen zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
30.01.23	Eisai : Lecanemab Receives Priority Review Status In Japan For Alzheimer's Disease Treatment (RTTNews)
30.01.23	LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN (PR Newswire)
27.01.23	Eisai : EMA Accepts MAA For Lecanemab As Treatment For Early Alzheimer's Disease (RTTNews)
27.01.23	MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE ACCEPTED BY EUROPEAN MEDICINES AGENCY (PR Newswire)
16.01.23	EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN (PR Newswire)
11.01.23	Eisai Submits MAA For Lecanemab As Treatment For Early Alzheimer's Disease In Europe (RTTNews)
11.01.23	EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE (PR Newswire)
07.01.23	Eisai Submits SBLA To FDA For Traditional Approval Of Leqembi For Alzheimer's Disease Treatment (RTTNews)
07.01.23	FDA Approves Eisai And Biogen's Leqembi For Alzheimer's Disease Treatment (RTTNews)
07.01.23	Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease (PR Newswire)
06.01.23	Biogen-Aktie an der NASDAQ fester: US-Arzneibehörde erteilt Zulassung von Biogen Alzheimer-Medikament (AWP) Die US-Arzneibehörde FDA hat eine beschleunigte Zulassung für ein Antikörper-Medikament vergeben, das ein Fortschreiten von Alzheimer im frühen Stadium verlangsamen soll.» mehr
06.01.23	FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease (PR Newswire)
04.01.23	Biogen Announces License Agreement With Alcyone For ThecaFlex DRx System (RTTNews)
30.12.22	Congress Report Says FDA Broke Protocols In Approval Of Biogen Alzheimer's Drug (RTTNews)
23.12.22	EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA (PR Newswire)
19.12.22	Roche-Aktie stabil: Genentech und Biogen einigen sich bei Vermarktung von Glofitamab (AWP) Die Roche-Tochter Genentech und das US-Biotechunternehmen Biogen haben die künftigen Vermarktungsdetails für die Krebstherapie Glofitamab ausgehandelt.» mehr
19.12.22	Biogen Signs Agreement With Genentech For Royalties On Glofitamab (RTTNews)
09.12.22	Biogen : FDA Accepts BLA For BIIB800, Biosimilar Candidate Referencing ACTEMRA (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	596.00	1.78 %	K V
Alcon	82.66	1.40 %	K V
Sonova Hldg	323.70	1.19 %	K V
Geberit	502.80	0.72 %	K V
Sika	234.30	0.69 %	K V
Swiss Re	139.60	-0.18 %	K V
Holcim	90.32	-0.22 %	K V
Zurich Insur Gr	546.00	-0.29 %	K V
ABB	50.68	-0.31 %	K V
Kuehne+Nagel Int	206.00	-0.43 %	K V

mehr

09:28		Börse Frankfurt in Grün: TecDAX zum Start mit Gewinnen
09:28		Freundlicher Handel: Euro STOXX 50 zum Start in Grün
09:28		XETRA-Handel: DAX klettert zum Start des Dienstagshandels
09:28		Schwacher Handel: MDAX beginnt die Sitzung weit in der Verlustzone
09:28		Minuszeichen in Frankfurt: LUS-DAX startet in der Verlustzone

09:28

Börse Frankfurt in Grün: TecDAX zum Start mit Gewinnen

09:28

Freundlicher Handel: Euro STOXX 50 zum Start in Grün

09:28

XETRA-Handel: DAX klettert zum Start des Dienstagshandels

09:28

Schwacher Handel: MDAX beginnt die Sitzung weit in der Verlustzone

09:28

Minuszeichen in Frankfurt: LUS-DAX startet in der Verlustzone